Characterization of the function and clinical value of ERCC family genes in lung adenocarcinoma

被引:0
作者
Lu, Zhimin [1 ]
Hou, Guoxin [2 ]
机构
[1] Jiaxing Univ, Affiliated Hosp, Hosp Jiaxing 1, Dept Outpatient, Jiaxing, Peoples R China
[2] Jiaxing Univ, Affiliated Hosp, Hosp Jiaxing 1, Dept Oncol, Jiaxing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
中国国家自然科学基金;
关键词
ERCC genes; lung adenocarcinoma; bioinformatic; tumor infiltrating lymphocytes; ERCC8; CANCER SUSCEPTIBILITY; POLYMORPHISMS; PLATINUM; PROLIFERATION; OSTEOSARCOMA; ASSOCIATION; EXPRESSION; SURVIVAL; NETWORK; CELLS;
D O I
10.3389/fonc.2024.1476100
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction ERCC genes, responsible for encoding enzymes involved in base excision repair, have been implicated in various cancers, contributing to chemoresistance. However, a comprehensive analysis of the prognostic and therapeutic significance of this gene family in lung adenocarcinoma (LUAD) is lacking.Methods This study conducted a multidimensional assessment of ERCC family genes in LUAD using bioinformatic approaches, including mRNA expression level, gene methylation, and copy number variation (CNV), as well as their correlations with clinical outcome, gene set variations, and tumor-infiltrating lymphocytes (TILs). In addition, We evaluated the anti-tumor effects of ERCC8 in cell lines, demonstrating its clinical potential on an experimental level.Results Overall, the expression of ERCC genes exhibited a negative correlation with good prognosis, with ERCC6L and ERCC8 demonstrating the most reliable predictive performance. Gene methylation level and CNV increases of ERCC genes generally displayed negative and positive associations with their expression levels, respectively. Additionally, GSVA analysis suggested that ERCC expression was positively correlated with cell cycle and apoptosis pathways but negatively correlated to the TSC/mTOR pathway. Furthermore, the expression of ERCC genes exhibited a complex relationship with TILs and the response to anti-tumor drugs. The results of in vitro cellular experiments show that inhibiting ERCC8 can alleviate the malignant phenotype of LUAD cells.Discussion Our study revealed the multifaceted biological and clinical significance of ERCC family members in LUAD. These findings provide new insights into the function of ERCC family genes in LUAD and their potential clinical applications.
引用
收藏
页数:17
相关论文
共 43 条
  • [1] Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
    Basourakos, Spyridon P.
    Li, Likun
    Aparicio, Ana M.
    Corn, Paul G.
    Kim, Jeri
    Thompson, Timothy C.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2017, 24 (15) : 1586 - 1606
  • [2] Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]
  • [3] Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis
    Cao Chao
    Zhang Yan-mei
    Wang Ran
    Sun Shi-fang
    Chen Zhong-bo
    Ma Hong-ying
    Yu Yi-ming
    Ding Qun-li
    Shu Li-hua
    Deng Zai-chun
    [J]. CHINESE MEDICAL JOURNAL, 2011, 124 (14) : 2203 - 2208
  • [4] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
    Cerami, Ethan
    Gao, Jianjiong
    Dogrusoz, Ugur
    Gross, Benjamin E.
    Sumer, Selcuk Onur
    Aksoy, Buelent Arman
    Jacobsen, Anders
    Byrne, Caitlin J.
    Heuer, Michael L.
    Larsson, Erik
    Antipin, Yevgeniy
    Reva, Boris
    Goldberg, Arthur P.
    Sander, Chris
    Schultz, Nikolaus
    [J]. CANCER DISCOVERY, 2012, 2 (05) : 401 - 404
  • [5] PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
    Chabanon, Roman M.
    Muirhead, Gareth
    Krastev, Dragomir B.
    Adam, Julien
    Morel, Daphne
    Garrido, Marlene
    Lamb, Andrew
    Henon, Clemence
    Dorvault, Nicolas
    Rouanne, Mathieu
    Marlow, Rebecca
    Bajrami, Ilirjana
    Cardenosa, Marta Llorca
    Konde, Asha
    Besse, Benjamin
    Ashworth, Alan
    Pettitt, Stephen J.
    Haider, Syed
    Marabelle, Aurelien
    Tutt, Andrew N. J.
    Soria, Jean-Charles
    Lord, Christopher J.
    Postel-Vinay, Sophie
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (03) : 1211 - 1228
  • [6] Chen XJ, 2018, EUR REV MED PHARMACO, V22, P6658, DOI 10.26355/eurrev_201810_16142
  • [7] Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019
    Fan, Yaguang
    Jiang, Yong
    Gong, Lei
    Wang, Ying
    Su, Zheng
    Li, Xuebing
    Wu, Heng
    Pan, Hongli
    Wang, Jing
    Meng, Zhaowei
    Zhou, Qinghua
    Qiao, Youlin
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [8] Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis
    Feng, Zhen
    Ni, Yang
    Dong, Wei
    Shen, Hongchang
    Du, Jiajun
    [J]. MOLECULAR BIOLOGY REPORTS, 2012, 39 (01) : 57 - 69
  • [9] Innate and adaptive immune cells in the tumor microenvironment
    Gajewski, Thomas F.
    Schreiber, Hans
    Fu, Yang-Xin
    [J]. NATURE IMMUNOLOGY, 2013, 14 (10) : 1014 - 1022
  • [10] Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway
    Ge, Yiqin
    Xu, Kan
    [J]. CANCER CELL INTERNATIONAL, 2016, 16